 Isoniazid
"Isoniazid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
| Descriptor ID |
D007538
|
| MeSH Number(s) |
D02.442.436 D03.066.349.410 D03.383.725.394.582
|
| Concept/Terms |
Isoniazid- Isoniazid
- Isonicotinic Acid Hydrazide
- Hydrazide, Isonicotinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Isoniazid".
Below are MeSH descriptors whose meaning is more specific than "Isoniazid".
This graph shows the total number of publications written about "Isoniazid" by people in UAMS Profiles by year, and whether "Isoniazid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 2 | 3 | | 2015 | 2 | 2 | 4 | | 2014 | 2 | 1 | 3 | | 2013 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2001 | 1 | 2 | 3 | | 1999 | 0 | 2 | 2 | | 1996 | 1 | 0 | 1 | | 1995 | 1 | 1 | 2 | | 1993 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Isoniazid" by people in Profiles over the past ten years.
-
Syed RR, Catanzaro DG, Colman RE, Cooney CG, Linger Y, Kukhtin AV, Holmberg RC, Norville R, Crudu V, Ciobanu N, Codreanu A, Seifert M, Hillery N, Chiles P, Catanzaro A, Rodwell TC. Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. J Clin Microbiol. 2023 03 23; 61(3):e0147822.
-
Demers AM, Kim S, McCallum S, Eisenach K, Hughes M, Naini L, Mendoza-Ticona A, Pradhan N, Narunsky K, Poongulali S, Badal-Faesen S, Upton C, Smith E, Shah NS, Churchyard G, Gupta A, Hesseling A, Swindells S. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. BMC Infect Dis. 2021 Feb 24; 21(1):205.
-
Xu Y, Wang L, Zimmerman MD, Chen KY, Huang L, Fu DJ, Kaya F, Rakhilin N, Nazarova EV, Bu P, Dartois V, Russell DG, Shen X. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. PLoS Pathog. 2018 04; 14(4):e1006974.
-
Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, Wang SH, Stewart B, Griffin P, Hunt G, Shah N, Marco A, Patil N, Mukasa L, Moro RN, Jereb J, Mase S, Chorba T, Bamrah-Morris S, Ho CS. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. Clin Infect Dis. 2017 10 01; 65(7):1085-1093.
-
Georghiou SB, Seifert M, Lin SY, Catanzaro D, Garfein RS, Jackson RL, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC. Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis. BMC Infect Dis. 2016 08 31; 16:458.
-
Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC. Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother. 2016 07; 60(7):3994-4004.
-
Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, Chen C, Dartois V, VanderVen BC, Russell DG. Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo. J Exp Med. 2016 05 02; 213(5):809-25.
-
Torres JN, Paul LV, Rodwell TC, Victor TC, Amallraja AM, Elghraoui A, Goodmanson AP, Ramirez-Busby SM, Chawla A, Zadorozhny V, Streicher EM, Sirgel FA, Catanzaro D, Rodrigues C, Gler MT, Crudu V, Catanzaro A, Valafar F. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect. 2015 Jul; 4(7):e42.
-
Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, Ambroso JI, Falls JG, Hunt CM. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase?. Regul Toxicol Pharmacol. 2015 Aug; 72(3):481-90.
-
Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015; 10(3):e0119628.
-
Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
-
Ajbani K, Lin SY, Rodrigues C, Nguyen D, Arroyo F, Kaping J, Jackson L, Garfein RS, Catanzaro D, Eisenach K, Victor TC, Crudu V, Gler MT, Ismail N, Desmond E, Catanzaro A, Rodwell TC. Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries. Antimicrob Agents Chemother. 2015 Jan; 59(1):414-20.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|